President BidenJoe BidenGallego on Jan. 6 Rioters: “F— them” Psaki: Why is the GOP afraid of presidential debates? Biden calls on employers to make vaccines mandatory despite Supreme Court ruling MOREchief medical adviser Antoine FauciAnthony FauciThe Hill’s 12:30 Report: Biden strategizing with Senate Democrats Scientists and medical professionals defend Fauci after heated exchanges with Republicans Doctors call Spotify out on ‘false claims harmful to society’ on Joe Rogan show MORE said in an interview that it’s not yet clear if people will need annual booster shots of COVID-19, even though chief executives of several drugmakers have indicated a fourth dose of the vaccine may be needed.
“We only reinforced people recently. We’ll find out if the booster gives you a long-lasting degree of protection and should actually be the standard regimen of three doses of mRNA and two doses of J&J,” Fauci said in a statement. interview with NBC News published Thursday.
“Or – and that’s a big ‘or’ right now – will we need to boost people every year or so?” He continued.
Fauci said that while it was a good thing that the original ancestral strain of COVID-19 was used in the development of the COVID-19 vaccine – because “we were lucky that even though [strains] were different, they weren’t so different that the vaccine didn’t cover it well” — omicron confused the situation.
“We were doing pretty well with a primary shot and a boost with delta. Then all of a sudden omicron came along,” Fauci told the network. “And if you look at the efficiency against the delta versus the omicron, it’s gone down to about 30 percent.”
The leading infectious disease expert said he wanted a vaccine that would ideally be effective against all sorts of variants of COVID-19.
Fauci’s remarks come as chief executives of drugmakers like Pfizer and Moderna have suggested people may need a fourth dose of the COVID-19 vaccine amid concerns about the omicron variant and dwindling recall effectiveness.
“I think we will need the fourth dose,” Pfizer CEO Albert Bourla told CNBC last month.
“With omicron, we have to wait and see because we have very little information. We may need it sooner,” than a previous 12-month delay, which Bourla had considered administering a fourth dose after the One individual’s initial recall, the CEO mentioned.